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Evidence supporting an immune complex pathogenesis 
of bullous lesions in systemic lupus erythematosus in-
cludes immune deposits, acute inflammation, and blister 
formation at the cutaneous basement membrane zone. 
Since cutaneous immune deposits are a general feature 
of lupus, an attempt has been made to determine whether 
deposits in lupus patients with blisters are functionally 
different from those in patients without blisters. Skin 
was obtained from 4 consecutive patients with blisters 
and 14 controls. The groups were matched for clinical 
and serologic features, duration and activity of disease, 
and treatment. Skin was examined by direct immunoflu-
orescence for immune deposits and by the leukocyte 
attachment assay for quantification of complement-ac-
tivating immune complexes. Clinically normal, viable 
skin from 1 patient with blisters and 1 patient without 
blisters was incubated in organ culture with normal 
human leukocytes and serum complement. All patients 
in both groups had immune deposits at the basement 
membrane zone with an equivalent incidence of the 
major lg classes. Deposits in patients with blisters were 
slightly more intense and a linear pattern of fluores-
cence seen in 75% of these patients was not seen in 
controls. The leukocyte attachment assay showed sig-
nificantly greater (p < .02) cell attachment in patients 
with blisters (mean = 167) than in patients without 
blisters (mean = 64) and greater cell attachment in 
peribullous than normal skin from the same patient. 
Organ culture showed complement-dependent migration 
of leukocytes and histologic features similar to those in 
spontaneous lesions in skin from the patient with blisters 
but not in skin from the patient without blisters. These 
results provide evidence supporting immune complex 
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and complement-dependent inflammation in the patho-
genesis of bullous lesions in systemic lupus erythemato-
sus. 
The majority of patients with system ic lupus erythematosus 
(SLE) have specific cutaneous manifestations of the disease 
[1,2]. Most lesions are characterized by immune complexes at 
the basement membrane zone (BMZ) and chronic inflam-
mation in the upper dermis [3-7]. The importance of complexes 
in the pathogenesis of the lesions has been questioned for 
several reaso ns including the fact that the histologic features 
usually resemble t hose of cell -mediated rather than immune 
complex-mediated inf1ammation [8,9]. 
In recent years, a number of patients with SLE and bullous 
lesions have been reported as cases of bullous SLE (BSLE) or 
bullous eruption of SLE [10- 13]. The clinical and immuno-
pathologic features of lesions have closely resembled each other 
and the features of immune complex-mediated inf1ammation. 
The immunohistologic features have been similar to those 
described in SLE patients without blisters; however, the his-
to logy has been characterized by acute inflammation. The 
features characteristic of these lesions have not been desc ribed 
in patients without SLE nor in any primary vesiculobu llous 
disease, supporting the view that t he blisters are a specific, 
though uncommon, manifestation of SLE and not SLE and a 
coexistent bullous disease. 
Evidence suggesting cutaneous immune complexes play a 
role in the pathogenesis of BSLE les ions is based on the 
similarities between t he immunopathologic features of blisters 
and immune complex-mediated lesions in animal models of 
experimental immune complex disease [8,14-16]. Evidence 
against their role is the fact that deposits with a s imilar com-
position and site of deposition are present in the majority of 
SLE patients, most of whom develop neither acute inflam-
mation nor blisters. A possible explanation is that complexes 
in pat ients with blisters possess inf1ammatory properties which 
are quali tatively or quantitatively different from those in pa-
tierits without blisters. A property of complexes that .may 
determine their abi li ty to cause inflammation is activation of 
the complement system. Differences in complement act ivation 
at the BMZ, due to more complement-activating complexes or 
more efficient activation of complement, could be responsible 
for acute inf1ammation in some patients. 
In the past several years, we have had t he opportunity to 
examine and obta in skin biopsies from 4 consecutive patients 
with BLSE and acute inf1ammation. In this study we examined 
the biopsies and those from a closely matched control popula-
t ion of SLE patients with cutaneous immune deposits but 
without blisters. All biopsies were examined by direct immu-
nof1uorescence and a functional in vitro method to detect and 
quantify complement activation by in vivo deposited complexes. 
In addition, we incubated clinically normal , viable skin from 1 
BLSE and 1 control patient in organ culture with normal 
human leukocytes and serum complement. This experiment 
was performed to determine whether immune complexes in 
intact viable skin could activate complement, mediate the ac-
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cumulation of leukocytes at the BMZ, and reproduce some of 
t he histologic features of spontaneous lesions. Together t he 
results of t hese experiments provide functional support to the 
desc riptive evidence suggesting immune complexes may play a 
pathogenetic role in some bullous lesions of SLE. 
CASE SUMMARIES 
Detailed case histories of patients #1 a nd #2 have been published 
e lsewhere [13]. Brief case summaries of patients #3 a nd #4 are pre-
sented below. 
BSLE Case #3: Pat ient #3 was a 21-year-o ld woman wi t h SLE 
man ifested by arthralgias, photosensit ivity , a lopecia, nephri t is, a posi-
tive fluorescent a ntinuclear a nt ibody test (FANA) at a t iter of 1:512, 
a nt ibodies to Sm and ribonucleoprotein antigens, and hypocomplemen-
temia. There was a 6-month history of a n intermittent, bullous eruption 
involving the face, neck, shoulders, a nd proximal upper extremities. 
The histology of peribullous skin showed an intense infil t rate of neu-
t rophils in t he upper dermis a nd papillary microabscesses. Direct 
immunofluorescence of normal and peri lesional skin showed linear 
deposits of IgG, lgA, lgM, a nd C3 at the BMZ a nd trace depos its of 
IgM a nd C3 in vesse ls. Indirect immunofluorescence for ant i-BMZ 
antibodies was negative. Immunoelectron microscopy of perilesional 
s kin showed immune deposits and dermal-epidermal separation be-
n eath the basal lam ina. The les ions responded rapidly to diaminodi-
p henylsulfone (200 mg per day). 
BSLE Case #4: Patient #4 was a 33-year-old woman with SLE 
characte ri zed by arthralgias , photosensitivity, fevers, a posit ive FANA 
at a t ite r of 1:250, elevated levels of circulating immune complexes, 
non hemolytic a nemia, leukopenia, hypocomplementemia, a nd ant ibod-
ies to Sm, SSA, and SSB ant igens. The pat ient had a 2- month histo ry 
of a genera lized bullous erupt ion. Routine histology of periles ional skin 
s howed neutrophilic microabscesses and microvesicles at t he BMZ. 
Direct immunofluorescence of periles iona l and normal skin showed 
moderate ly intense granula r deposits of IgG, IgM, a nd C3 at t he BMZ. 
Circulating anti -BMZ ant ibodies were not detectable. lmmunoelectron 
microscopy of peri lesional skin showed immune deposits in the upper 
dermis just beneath t he basal lam ina. Lesions responded slowly to 
prednisone (1- 2 mg/kg per day). 
MATERIALS AND METHODS 
BSLE 
The patients used in t his study (BSLE cases 1- 4) represent a ll 
patients with BLSE seen by us s ince 1977. Each met the classification 
criteria of t he American Rheumatism Association (ARA) for SLE prior 
to or at the onset of the bullous eruption [1 7]. In each, an acqui red 
vesiculobullous disease other than BLSE was excluded on t he basis of 
clinical, microbiologic, histologic, immunohistologic, and immunoelec-
t ron microscopic studies. 
Controls 
Co nt rols for t his study were 14 pat ients wi t h active SLE without a 
history or clinical evidence of a bullous eruption. All patients met ARA 
cri teria for SLE. Controls were selected in pa rt on t he basis of a known 
positive lupus ba nd test (LBT) . An attempt was made to obta in patients 
wit h clinica l a nd sero logic features that matched those of patients with 
BSLE a nd t hat would selec t for heavy depos ition of immune reactants 
in skin. These features include antibodies to DNA, hypocomplemen-
temia, nephritis, active disease, a nd absence of or a short duration of 
immunosuppressive treatment [18,19]. In addit ion, patients were 
matched as closely as possible for race, sex, age, and duration of SLE. 
Shin 
Punch biopsies of skin (3-4 mm) were obtai ned from BSLE a nd 
contro l SLE (CSLE) pat ients under local 1% Xylocaine anesthesia , 
quick-frozen in liquid N2, mounted in Ames OCT compound (Miles 
Lab, Elkhart, India na), and stored at -70"C. Biopsies from BSLE were 
obtained from unexposed (3) or exposed (1) normal skin a nd per ile-
sional skin (4). Biopsies from CSLE were obta ined from normal ex-
posed (8) or unexposed (6) skin . Following informed consent , 2 cm2, 
0.4 mm-thick specimens of skin were keratomed from normal buttock 
in BSLE patient #3 and CSLE patient #10 using sterile procedures and 
1% Xylocaine anesthesia. The skin was immediately placed in minimal 
essential medium (MEM) conta ining Hanks' balanced salts a nd 5% 
heat-inactivated (56"C x 30 min) fetal calf se rum (MEM-FCS). 
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Normal Human Peripheral Blood Leuhocytes (PEL) and Fresh-Frozen, 
Platelet-Poor Serum (NHS) 
PBL and NHS were obtained from normal volunteers and prepared 
as previously desc ribed [20]. Heat-inactivated NHS (NHS 1) was pre-
pared by heating NHS at 56"C X 30 min just p rior to use. Dilu t ions of 
PBL, NHS, and NHS, were made in Gey's bala nced salt solution 
(GBSS) containing 2% bov ine serum a lbu min (Flow Lab, McLean , 
Virginia ) (MEM -FCS). 
Direct Immunofluorescence 
Direct immunof1uorescence was performed on 6 11m-t hick cryostat 
sections of skin using the method of Beut ner and Nisengard [21 ]. All 
reagents were f1uorescein isothiocyanate (FITC)-conjugated, monospe-
citic IgG fractions of goat-antisera to human proteins purchased from 
Cappel Labs, Cochranville, Pennsylvania. Specific ant ibody concentra-
t ions a nd molar f1 uoresce in to protein ratios were: Anti-IgG, 6.1 mg/ 
ml and 2.5; ant i-IgM, 2.5 mg/ml and 3.4; a nti-lgA, 3.0 mg/ml a nd 3.0; 
a nt i-C3, 3.0 mg/ml and 3.2 . All ant isera were used at a working dilution 
of 1:10 in 0.15 M NaCl buffered with 0.01 M NaHPO, and 0.01 M 
NaH 2P0,1, pH 7.2 (PBS) with 4% bovine serum albumin and 0.02 % 
sodium azide. 
Leuhocyte Attachment Assay 
T he leukocyte attachment (LA) assay was performed in t riplicate on 
6 11m-thick cryostat sections of skin as previously described [20]. T he 
assay was performed on tissue from BSLE biopsies using 10 x 106 
PBL/ ml suspended in 10% NHS or 10% NHS, in GBSS. CSLE biopsies 
were tested with PBL in NHS only. 
Quantification of Leukocyte Attachment 
Each slide was examined at 400X magn ification us ing a light micro-
scope equipped wit h a lOx fi lar linear micrometer eyepiece (American 
Optical Corp., Buffalo, New Yo rk). LA to the BMZ was quantified by 
count ing t he number of PBL/ mm of BMZ in 6- 8 random fields per 
s lide and a n average LA per slide determined. A mean LA ± SD was 
calculated for each biopsy from triplicate assays. 
Analysis of Results 
Mean LA in normal and peri les iona l BSLE skin in t he presence of 
NHS was compared with mean LA in CSLE skin a suming unequal 
variance between BSLE and CSLE groups and taking into accoun t t he 
unequal number of values (n) between t he groups. Analys is of means 
was performed by both pa rametric (1-ta iled t-test assuming an absence 
of correlation) a nd nonpa rametric (Wilcoxon ra nk sum) tests. Mean 
LA in normal and peri les ional BSLE skin was analyzed by 2-tailed t-
test assum ing a normal distribu t ion of values, a nd Wilcoxon rank sum 
test assuming no differences between t he means of the two groups. LA 
in BSLE skin performed with NHS or NHS, was compared using a 1-
ta iled t-test. 
Organ Culture Assay for Leuk.ocyte Migration Into Viable Shin 
Viable skin from BSLE patient #3 and from CSLE patient #10 was 
placed in a sterile Petri dish and strips 1-2 X 10 mm were cut wi th a 
razor blade. Strips were washed 3 t imes in sterile MEM and incubated 
immediate ly in sterile conical polypropylene microcentrifuge tubes 
(Fisher Scientific Co., P ittsburgh, Pennsylvania) containing 0.5 ml of 
40 x 106 PBL/ml a nd 25% NHS or NHS, in MEM-FCS. Incubation 
was performed at 37"C fo r 4 h with cont inuous gentle rotation of tubes. 
Experiments were performed in trip licate. Following incubation, skin 
strips were gent ly washed in PBS, fixed in forma lin, embedded m 
paraffin , stained with hematoxylin and eosin, and examined. 
RESULTS 
A comparison of the clinical, serologic, and t reatment fea-
tures in BSLE and CSLE patients is shown in Table I. The 
incidences of renal disease, anti-DNA antibodies, and hypo-
complementemia were higher in the CSLE group. Biopsies were 
from normal exposed skin in 9/14 (57%) of CSLE patients and 
1/4 (25 %) of BSLE patients. None of t he patients in either 
group had received cytotoxic therapy. Only 50% of the CSLE 
group had received prednisone compared to 100% in the BSLE 
group. Since systemic disease in the CSLE group seemed to be 
at least as severe as in the BSLE group , the smaller number of 
patients in t he CSLE group receiving prednisone probably 
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TABLE I. Clinical and serologic features in BSLE and CSLE patients 
Number of patients 
Age (years): 
Range 
Mean 
Sex (% females) 
Mean duration of SLE (months) 
Incidence of skin lesions (%) 
Incidence of lupus nephritis(%) 
Incidence of anti-DNA antibodies (%) 
Mean titer of anti -DNA antibodies 
Incidence of hypocomplementemia 
Prednisone therapy: 
BSLE 
4 
(16- 51) 
30 
100 
22.5 
100 
50 
50 
1:48 
75 
Percent t reated 100 
Mean duration of treatment (months) 7 
Dose range and mean (mg/day) 30- 120 (36) 
BSLE = bullous SLE; CSLE = control SLE. 
CSLE 
14 
(10- 49) 
22 
78 
11.5 
78 
78 
86 
1:114 
100 
50 
6 
15- 60 (32) 
TABLE II. Direct immunofluorescence of bullous and control SLE skin 
Patient# Intensity• Pattern• IgG lgA lgM C3 
BSLE 
1 3+ L' + 0 + + 
2 3+ L + 0 0 + 
3 3+ L + + + + 
4 2+ G + 0 + + 
2.75d 100%' 25%' 75%' 100%' 
CSLE 
1 3+ G + 0 + + 
2 2+ G + 0 0 0 
3 3+ F + + + + 
4 2+ G + 0 + + 
5 2+ F + 0 + + 
6 2+ G + 0 + + 
7 2+ F + 0 + 0 
8 1+ G + 0 0 + 
9 2+ G + + 0 0 
10 3+ G + + + + 
11 3+ G + + + + 
12 2+ G + 0 + + 
13 2+ G + 0 + + 
14 1+ F + 0 0 0 
2.1d 100%' 28%' 57%' 64%' 
L = linear; G = granular; F =fibrillar. 
"Determined using FITC-conjugated antihuman IgG. 
b Determined using FITC-conjugated antihuman IgG. 
' Scale of fluorescein intensity = 0 to +3. 
d Mean intensity of immunofluorescence. 
• Percent incidence. 
reflected the shorter duration of disease (11 .5 months compared 
to 22.5 months in the BSLE group) and attempts to control 
the skin eruption in BSLE patients. No significant differences 
in either the duration (7 vs 6 months) or mean dose of predni-
sone (36 vs 32 mg/d) were seen between the groups. The mean 
age of patients in the CSLE group (22 years) was less than in 
the BSLE group (30 years). There was no significant difference 
in t he sex distribution, and the incidence of nonbullous cuta-
neous manifestations of SLE was similar. 
Direct Immunofluorescence 
The results of direct immunofluorescence in BSLE and 
CSLE sk in biopsies are shown in Table II. All biopsies had 
deposits of lg at the BMZ (positive LET). The findings in 
normal and perilesional skin in BSLE biopsies were identical 
for each patient. The intensity and pattern of immunofluores-
cence recorded in Table II were those observed with FITC anti-
lgG. The patterns observed with the other conjugates were 
similar. In a ll biopsies IgG immunofluorescence was the most 
intense. The incidences of lgG, lgA, and lgM deposits were 
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very similar for both groups. C3 deposits were present in 100% 
of BSLE biopsies and in 64% of CSLE biopsies. By subjective 
assessment, the intensity of lgG fluorescence in BSLE biopsies 
was greater t han in CSLE biopsies (2 .75 vs 2.1 on a scale of 0-
3). We cou ld appreciate no differences in intensity of fluores-
cence or in type of immune reactants between perilesional and 
normal BSLE skin. Of special interest was t he presence of a 
linear pattern of immunofluorescence in 3 of 4 patients in the 
BSLE group. Linear flu orescence was not seen in a ny biopsies 
from the CSLE group. An example of the linear immunoflu-
orescent pattern in BSLE patient #3 is shown in Fig 1. 
Leuhocyte Attachment 
LA in normal and perilesional skin from BSLE patients #1 -
4 is shown in Table III and Fig 2. In normal BSLE skin, the 
FIG 1. An example of linear IgG BMZ immunofluorescence in nor-
mal sk in from patient #3. x 800. 
TABLE Ill. Results of leukocyte attachment in CSLE and BSLE skin" 
BSLE 
CSLE1' 
102 ± 11 
59± 12 
46 ± 14 
20 ± 6 
56± 12 
71 ± 8 
59± 14 
106 ± 11 
40 ± 6 
88 ± 6 
27 ± 6 
76 ± 5 
73 ± 14 
70 ± 8 
64 ± 25 
Lesional skin 
NHS' NHS;d 
161 ± 35 67 ± 13 
146 ± 46 45 ± 16 
270 ±51 121 ± 32 
127 ±51 32 ± 12 
176 ± 64 66 ± 39 
Normal skin 
NI-lS NHS; 
142 ± 24 58± 8 
130 ± 20 57± 9 
255 ± 42 147 ± 38 
107 ± 24 60 ±" 9 
158 ±66 80 ± 44 
" Leukocyte attachment value expressed as number of peripheral 
blood leukocytes (PBL) mm basement membrane zone. CSLE =control 
SLE; BSLE = bullous SLE. 
b Leukocyte attachment performed with 10% fresh normal human 
serum only. 
' Leukocyte attachment performed with PBL in 10% fresh normal 
human serum. 
d Leukocyte attachment performed with PBL in 10% heat-inacti-
vated serum. 
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FIG 2. An example of LA on cryostat section of skin from BSLE 
patient #1 treated with PBL and NHS. Note the accumulation of 
neutrophils (n) in the upper dermis and just beneath the BMZ. He-
matoxylin & eosin, x 400. 
range of LA was 107 ± 24 to 255 ± 32 PBL/mm BMZ with a 
mean of 158 ± 66. In perilesional skin , the range was 127 ± 21 
to 270 ± 51 PBL/mm BMZ with a mean of 176 ± 64. By t-test 
a nalysis LA was significantly greater in perilesional compared 
to normal skin , (p = .00068). By Wilcoxon rank sum test, the 
differences were only significant at p = 0.1003. 
The results of LA in CSLE skin are also shown in Table III . 
LA ranged from 20-106 with a mean of64 ± 25 PBL/mm BMZ. 
A comparison of the mean LA values between groups showed 
significantly greater attachment in normal BSLE (p = .0035) 
and perilesional BSLE skin (p = .0029) compared to CSLE 
skin. 
To demonstrate a requirement for complement in LA in 
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munohistologic, and ult rastructural features in t hese patients 
suggest the bullous lesions are a specific manifestation of SLE 
and not a coexistent bullous disease and that immune com-
plexes may be responsible for blisters. All 13 patients have 
presented with SLE and blisters with a morphology and/or 
distribut ion resembling dermatitis herpetiformis or bullous 
pemphigoid. Four reported pat ients, and 1 ofthose in t his study 
had a rapid and complete response of blisters to sulfones [12]. 
In 12 patients the histology was described as acute inflam-
mation wit h neutrophilic microabscesses at the BMZ or in 
dermal papillae. In 5, leukocytoclasis was observed either 
around upper dermal blood vessels or at t he BMZ. In a ll 12, 
blisters were subepidermal and in those examined by electron 
microscopy, dermal-epidermal separation was below t he basal 
lamina [12,13]. 
BSLE skin, the LA assay was performed with PBL suspended C 
in 10% NHS; and results compared to those obtained when the 
assay was performed with 10% NHS. The results are shown in 
T able III. There was a significant decrease (p < .01) in LA in 
the presence of NHS;. 
Organ Culture 
Multiple sections (> 20) of all skin strips were examined. In 
none of the sections of CSLE skin incubated in NHS or NHS; 
and in none from BSLE skin incubated in NHS; was there 
evidence of leukocyte migration into skin. However, in all 
sections (> 20) of BSLE skin incubated in NHS, numerous 
neutrophil leukocytes had infiltrated the upper dermis and 
BMZ (Fig 3A-C). Along the BMZ, there were focal areas of 
BMZ separation resembling the microvesicles observed in the 
spontaneous lesions of BSLE patient #3. 
DISCUSSION 
In recent years, patients with SLE and bullous lesions with 
features suggestive of an immune complex-mediated pathogen-
esis have been reported (10- 13]. Including the patients in t his 
study, a total of 13 cases have been described. Although the 
number is small, it probably underrepresents the true incidence 
of the disorder since some patients have undoubtedly not been 
reported and others may have been reported as SLE and a 
coexistent bullous disease [12,13]. The clinical histologic, im-
• •• 
'· .... 
FIG 3. A , Spontaneous lesion from BSLE patient #3 showing subep-
idermal microvesiculation (u) and a subepidermal microabscess con-
taining intact and degenerating neutrophils (n.). a= Artefactual sepa-
ration of stratum corneum from epidermis. Hematoxylin & eosin, x 
500. B, Strip of keratomed skin from BSLE patient #3 incubated for 4 
h at 37•c wit h 40 x 106 PBL/ ml and 25% NHS in MEM-FCS. 
Numerous neutrophils (n) are present in the upper dermis and beneath 
the BMZ. Small foci of dermal -epidermal separation (s) were observed. 
Hematoxylin & eosin, x 400. C, Strip of keratomed skin from BSLE 
patient #3 incubated fo r 4 h at 3TC wi th 30 x 106 PBL/ ml and 25% 
NHS; in MEM-FCS. Simila r resu lts were seen in unincubated sections 
and incubated sections in which PBL were deleted. Hematoxylin & 
eosin, x 250. 
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Results of direct immunof1uorescence in 12 patients showed 
immune deposits at the BMZ of perilesional skin in 12 and in 
normal skin in 11. The deposits were characterized by the 
consistent presence of lgG (100%); a high incidence of lgA 
(54%), IgM (61 %), and C3 (92%); heavy deposits of lg described 
as "bright," "dense," or "intense" (60%); and a homogeneous 
"linear" or "band" pattern of immunofluorescence (61 %). In 
cases with the linear pattern in lesional skin, the same pattern 
was also seen in normal skin. In no case have anti-BMZ 
antibodies been reported. Results of immunoelectron micros-
copy have been reported in several patients including most of 
those with linear immunofluorescence and the deposits have 
been below the basal lamina at the site of dermal-epidermal 
separation [12,13]. 
Although some patients have resembled bullous pemphigoid, 
the histology response to sulfones, absence of anti-BMZ anti-
bodies, and the location of immune deposits below the basal 
lamina exclude that disease [22). Dermatitis herpetiformis 
could be considered in the 7 cases with IgA deposits; however, 
lgA deposits were always associated with lgG and usually lgM, 
which is unusual in dermatitis herpetiformis but characteristic 
of SLE [19,23). Additional evidence against dermatitis herpe-
tiformis has been the absence of HLA B8 and subtotal villous 
atrophy of the small bowel [12). 
To investigate the possibility that complexes may cause 
blisters, we examined complexes in BSLE and CSLE skin using 
immunofluorescence, LA, and organ culture. The results of 
direct immunofluorescence in BSLE and CSLE skin showed a 
similar composition and incidence of the major Ig classes; 
however, the intensity of IgG and the incidence of C3 deposits 
were greater in BSLE. These findings suggest the possibility 
that more complexes and possibly more complement-activating 
complexes are present at the BMZ in BSLE. 
An additional difference was the linear pattern of immune 
reactant deposition seen in 3 of 4 BSLE patients and in no 
controls. The significance of the pattern and its relationship to 
the greater intensity of immunofluorescence or LA results is 
not known. To our knowledge, the pattern has been previously 
reported only in primary bullous diseases associated with anti-
BMZ antibodies, normal and lesional skin in BSLE, rarely in 
the chronic atrophic or hyperkeratotic lesions of discoid lupus 
erythematosus, and never in the normal skin of SLE patients 
without blisters [24,25). Although anti-BMZ antibodies have 
not been reported in BSLE, the possibility that they may be 
present and cause the linear pattern cannot be excluded. Al-
though anti-BMZ antibodies have not been detected in SLE 
sera by standard indirect immunofluorescence, they have been 
detected in extracts of SLE skin and in sera using counter 
immunoelectrophoresis to extracted BMZ components 
[26- 28) . 
Quantitative and functional evidence for complement-acti-
vating complexes in BSLE skin was obtained with the LA 
assay. In the presence of serum complement, PBL attached to 
the BMZ of skin sections from all BSLE biopsies, producing a 
pattern resembling the accumulation of leukocytes seen in the 
upper dermis and at the BMZ in spontaneous lesions. Evidence 
that LA was complement-dependent in SLE biopsies was pro-
vided by the significant reduction in attachment observed when 
the test was performed in the presence of heat-inactivated 
(complement-depleted) serum. 
The results of the assay showed significantly greater attach-
ment in both normal and perilesional BSLE skin than in CSLE 
skin. In no biopsy of CSLE did LA approximate the mean LA 
in BSLE nor did the highest LA value in CSLE equal or exceed 
the lowest value in BSLE. Surprisingly, it was found that LA 
was significantly higher in perilesional BSLE skin than in 
normal BSLE skin. This difference suggests that the potential 
for complement activation is higher in lesional skin and pro-
vides even more support to the hypothesis that complement 
activation is involved in lesion pathogenesis. 
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Although we reported the results of the LA assay in only 14 
control patients in this study, we have performed the assay on 
more than 50 biopsies of normal and perilesional skin in over 
30 patients with SLE, 10 patients with discoid lupus erythe-
matosus, and 25 patients with bullous pemphigoid, dermatitis 
herpetiformis, epidermolysis bullosa acquisita, and other bul-
lous diseases associated with cutaneous immune deposits. Some 
ofthese results have been reported elsewhere [20,29]. With the 
exception of a few patients with an unusual disease having 
clinical and pathologic features resembling both bullous pem-
phigoid and epidermolysis bullosa acquisita, we have rarely 
encountered LA values approaching those reported in the only 
4 BSLE patients we have tested. 
Preliminary evidence was obtained that complement activa-
tion observed at the BMZ in cryostat sections of BSLE skin 
may be expressed in intact viable skin. When skin from BSLE 
patients #3 was incubated with PBL and fresh serum, a dense 
accumulation of leukocytes, mainly neutrophils, was observed 
in the upper dermis and at the BMZ. Evidence of leukocyte-
mediated injury in these sections was suggested by small foci 
of dermal-epidermal separation . Although additional experi-
ments of this kind are clearly needed, this result supports a 
role for immune complexes in the pathogenesis of bullous 
lesions. This method may be of value in examining the patho-
logic significance of cutaneous immune deposits in other dis-
eases. 
The results of this study provide descriptive and functional 
evidence supporting a role for complement-activating immune 
complexes in the pathogenesis of blisters in BSLE. They do 
not exclude a role for complexes in the pathogenesis of more 
common lesions of SLE including those associated with chronic 
inflammation, nor do they exclude a role for cellular immuno-
logic or even nonimmunologic factors in the pathogenesis of 
some BSLE lesions. 
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Specific Immunologic Tolerance to Dinitrofluorobenzene Following 
Topical Application of Dinitrothiocyanobenzene: Modulation by 
Suppressor T Cells 
MASAFUMIIIJIMA, M.D . AND S TEPHEN I. K ATZ, M .D ., PH.D . 
Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U. S . A. 
In order to determine the mecha nism(s) involved in 
the induction of immunologic tolera nce for contact sen-
sitivity via the topical application of a chemical tha t 
sensitizes if given with adjuvant, we utilized the hapten 
dinitrothiocya nobenzene (DNTB). Specific immunologic 
tolerance to dinitrofluorobenzene (DNFB) was induced 
in mice by the topical application of DNTB 7 days before 
sensitization to DNFB. The tolerance could be a brogated 
if cyclophosphamide (200 mg/kg) was given 3 days be-
fore attempted sensitization. Using passive transfer 
studies we found that DNTB induced hapten-specific 
L y t 1 +2- suppressor T cells. These suppressor cells pre -
vented the induction of contact sensitivity but did not 
affect its expression. Lymphocyte proliferation studies, 
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Abbreviations: 
BSS: balanced salt solution 
CY: cyclophosphamide 
DNFB: dinit rot1uorobenzene 
DNP: dinit rophenyl 
DNTB: din itrothiocyanobenzene 
EC: epidermal cell (s) 
Epi: epicutaneous (application) 
FCA: Freund's complete adjuvant 
LNC: lymph node cells 
TNCB: t rini t rochlorobenzene (picryl chloride) 
using ha p tenated epiderma l cells as a n t igen , ind icate 
that lymph node cells obtained 5 days a f ter D NFB sen-
sitization a r e far less responsive if t he mice have re-
ceived DNTB epicutaneously 7 days before the DNFB. 
Binding studies demonstrated tha t DNTB bound t o epi-
derma l cells at least as well as did DNFB. It is pos tula ted 
tha t DNTB induction of suppressor cells is related to th e 
physicochemical intera ction between the hapte n and a n-
tige n-presenting cells in skin. 
Most studies of the mechanisms involved in immunologic 
unresponsiveness (toleran ce) in contact sensit ivity have used 
feeding or i.v. administration of various haptens in order to 
induce tolerance [1,2]. However, several studies have described 
the induction of tolerance in contact sensit ivity following the 
epicutaneous (Epi) application of eit her the hapten itself or of 
a cross-reacting chemical. When t he hapten is applied, eit her 
sub- or supraoptimal concent rations are used on normal skin 
[3- 6] or it is applied directly onto skin t hat has been irradiated 
with small amounts of UV [7], or to abdominal skin of mice 
which have received large amounts of UV irradiation to their 
dorsal skin [8]. Using these methods, the animals are unable 
to become sensit ized to t he haptens even when t he usual 
sensit izing dose is subsequent ly applied. 
Ot her methods used for the induction of tolerance for contact 
sensitivity include t he injection of t he hapten s.c. wit hout 
adjuvant (9], t he injection of a cross-reacting nonsensit izing 
chemical, or the applicat ion of a chemical which sensit izes for 
contact sensit ivity when it is emulsified with Freund's complete 
